New antibody offers hope for controlling devastating autoimmune disease
NCT ID NCT07405970
Summary
This study is testing whether a new antibody treatment called MIL62 can help control systemic lupus erythematosus, a serious autoimmune disease. About 316 adults with active lupus will receive either MIL62 or a placebo injection over 52 weeks to see if it reduces disease activity and allows patients to lower their steroid doses. Researchers will measure how well it controls symptoms, its safety, and its effect on quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University People's Hospital
Beijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.